InsidersTradesSigma
Total declarations
Companies
▲ Purchases (5 ops.)
▼ Sales (4 ops.)
Insider track record
Board DirectorDisclosed buys
5
Disclosed sells
4
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the complete record of transactions filed by WIGGANS THOMAS G, Director. Insider active across 4 companies, notably Forma Therapeutics Holdings, Inc.. Aggregated, 14 disclosures have been recorded. Split: 5 buys · 4 sells. Total volume traded: €55k. Activity tracked since 17 June 2021. The latest transaction was filed on 28 November 2023 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations14 total
10,000 shares@ US$0.648634.3% of flowVoting Common StockSEC:0001213900-23-091458:0
Ideal exit: 24 Aug 2024 (T+270)
10,000 shares@ US$0.638333.8% of flowVoting Common StockSEC:0001213900-23-089579:0
Ideal exit: 17 Aug 2024 (T+270)
10,000 shares@ US$0.596531.9% of flowVoting Common StockSEC:0001213900-23-088896:0
Ideal exit: 12 Aug 2024 (T+270)
50,000 sharesCommon StockSEC:0001209191-23-047836:0
12,500 shares@ US$1.0934.1% of flowCommon StockSEC:0001209191-22-060154:0
Ideal exit: 1 Sept 2023 (T+270)
25,000 shares@ US$1.0465.9% of flowCommon StockSEC:0001209191-22-059677:0
Ideal exit: 28 Aug 2023 (T+270)
7,250 sharesCommon StockSEC:0000899243-22-033650:0
4,500 shares0Common StockSEC:0000899243-22-021666:0
2,750 shares0Common StockSEC:0000899243-21-025095
2,750 shares0Common StockSEC:0000899243-21-025095:0
8,700 sharesCommon StockSEC:0001562180-16-001471:0
300 sharesCommon StockSEC:0001562180-16-001471:1
10,492 sharesCommon StockSEC:0001562180-16-001270:0
508 sharesCommon StockSEC:0001562180-16-001270:1
14 of 14 declarations
About WIGGANS THOMAS G
Thomas G. Wiggins is a Board Member at Forma Therapeutics Holdings, Inc. He contributes to the governance of the company and strategic decision-making. His experience in the biopharmaceutical sector is valuable in guiding the company's initiatives. As a board member, he ensures that Forma Therapeutics meets its performance and innovation objectives.
